ALK CEO: We call the FDA on a daily basis

Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Dansk biotekboss rejser 91 mio til at udfordre Novo Nordisk

Et amerikansk biotekselskab, som er grundlagt af en dansk molekylærbiolog, har rejst 91 mio. kr. til at fremme programmer inden for diabetes, fedme og fedtlever, herunder et "transformativt" diabeteslægemiddel rettet mod biologiske mål, som Novo Nordisk også arbejder med.

Related articles